January 11, 2018 / 10:06 PM / 9 months ago

BRIEF-Aradigm - FDA Advisory Committee Did Not Recommend Approval For Linhaliq

Jan 11 (Reuters) - Aradigm Corp:

* ARADIGM REPORTS RESULTS OF FDA ADVISORY COMMITTEE MEETING ON LINHALIQ‍​

* ARADIGM CORP - ‍FDA HAS SET A PDUFA ACTION DATE OF JANUARY 26, 2018 FOR COMPLETION OF ITS REVIEW OF LINHALIQ​

* ARADIGM CORP - ‍FDA ADAC DID NOT RECOMMEND APPROVAL FOR LINHALIQ AS A TREATMENT FOR NCFBE PATIENTS WITH CHRONIC LUNG PSEUDOMONAS AERUGINOSA INFECTIONS​

* ARADIGM - ADAC VOTED 12 “NO” TO 3 “YES”, 1 ABSTENTION, ON QUESTION OF CO’S PROVISION OF EVIDENCE OF SAFETY & EFFICACY OF CIPROFLOXACIN DISPERSION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below